Gonorrhea continues to pose a significant threat to global public health as infection rates climb and antibiotic resistance sweeps the world, leaving fewer treatment options. Recent research points towards the potential of existing MenB vaccines in offering protection against this pervasive sexually transmitted infection.
Study Design and Methods
A comprehensive systematic review was conducted, searching through PubMed, Embase, and Scopus databases without language restrictions up to December 10th, 2024. Two independent researchers extracted relevant data, focusing on the effectiveness of outer membrane vesicle (OMV)-based MenB vaccines in preventing N. gonorrhoeae infections. The analysis included various effect estimates such as odds ratios, relative risks, hazard ratios, and prevalence ratios, with vaccine effectiveness (VE) calculated accordingly.
Effectiveness of OMV-Based Vaccines
The review identified nine studies that met the inclusion criteria, comprising eight observational studies and one randomized clinical trial. Findings revealed that individuals vaccinated with OMV-based MenB vaccines experienced a significant reduction in gonorrhea diagnoses. The pooled effect size indicated a 30% vaccine effectiveness, underscored by a 95% confidence interval ranging from 19% to 39%, and statistical significance with p-values less than 0.001.
Key inferences from the study include:
- OMV-based vaccines may offer cross-protection against N. gonorrhoeae.
- Even partial effectiveness can significantly impact public health strategies.
- Real-world observational data supports the potential use of existing vaccines for gonorrhea prevention.
The findings suggest that repurposing MenB vaccines could be a practical interim measure in the fight against gonorrhea, potentially alleviating the burden of antibiotic-resistant strains. Public health authorities may consider integrating OMV-based vaccines into broader prevention programs while further randomized clinical trials are underway to solidify these preliminary results. This approach could bridge the gap until more targeted gonorrhea vaccines become available, offering immediate benefits in controlling the spread of this resilient infection.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
